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Sequencing individual genes by Sanger sequencing is
a time-consuming and costly approach to resolve clin-
ically heterogeneous genetic disorders. Panel testing
offers the ability to efficiently and cost-effectively
screen all of the genes for a particular genetic disor-
der. We assessed the analytical sensitivity and speci-
ficity of two different enrichment technologies, solu-
tion-based hybridization and microdroplet-based PCR
target enrichment, in conjunction with next-genera-
tion sequencing (NGS), to identify mutations in 321
exons representing 12 different genes involved with
congenital muscular dystrophies. Congenital muscu-
lar dystrophies present diagnostic challenges due to
phenotypic variability, lack of standard access to and
inherent difficulties with muscle immunohistochem-
ical stains, and a general lack of clinician awareness.
NGS results were analyzed across several parameters,
including sequencing metrics and genotype concor-
dance with Sanger sequencing. Genotyping data
showed that both enrichment technologies produced
suitable calls for use in clinical laboratories. However,
microdroplet-based PCR target enrichment is more
appropriate for a clinical laboratory, due to excellent
sequence specificity and uniformity, reproducibility,
high coverage of the target exons, and the ability to
distinguish the active gene versus known pseudo-
genes. Regardless of the method, exons with highly
repetitive and high GC regions are not well enriched
and require Sanger sequencing for completeness. Our
study demonstrates the successful application of tar-
geted sequencing in conjunction with NGS to screen
for mutations in hundreds of exons in a geneticallyheterogeneous human disorder. (J Mol Diagn 2012, 14:
233-246; DOI: 10.1016/j.jmoldx.2012.01.009)
Next-generation sequencing (NGS) applications can
have a tremendous impact on molecular medicine.1 Se-
quencing whole genomes for personalized medicine may
soon become possible with next-generation sequencing
applications, such as whole-genome de novo sequenc-
ing, transcriptome sequencing, microRNA profiling, and
targeted sequencing.2–5 Technological advances have
significantly increased the speed and throughput while
decreasing the cost for these applications.6–9 At present,
targeted analysis of candidate genes is most suitable for
diagnostic applications facilitating functional interpreta-
tion of sequence variations and overcoming limitations in
computational power.10 DNA diagnostic sequencing of
selected genes consists of two steps: an enrichment step
and massive parallel sequencing using one of the com-
mercially available NGS platforms.
A variety of methods have been developed in the last
few years to enrich a selected portion of the genome,
including solid phase–based microarrays11–15 and solu-
tion phase–based methods, namely, SureSelect (SS).16
These strategies have the ability to enrich for megabase
intervals or a full complement of protein-coding exons
(exome). An alternative approach has been developed
for enrichment of a desired genomic region by a micro-
droplet-based PCR approach, RainDance Technologies
(RDT).17 This technology uses emulsion chemistry to
generate millions of microdroplet-based PCR reactions,
each representing a single amplification of desired target
loci. Each droplet supports an independent PCR and is
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JMD May 2012, Vol. 14, No. 3made to contain a single primer pair, along with the
genomic DNA template and other reagents necessary for
the PCR reaction. The entire population of droplets rep-
resents hundreds to thousands of distinct primer pairs
and is subjected to thermal cycling, after which the emul-
sion is broken, and the PCR products are recovered. The
mixture of DNA amplicons can be subjected to shotgun
library construction and sequenced by NGS technology.
By combining these RDT and SS target enrichment tech-
nologies with NGS, they can become important sequenc-
ing tools with the potential to be implemented in a clinical
diagnostics laboratory. These enrichments methods and
NGS technologies are relatively new, and as such, quality
control of the sequence data has not yet been well de-
fined. Guidelines will need to be put in place before NGS
technology can be used routinely in molecular diagnos-
tics laboratories.
Some of the most common heterogeneous genetic dis-
orders for which genetic diagnosis is sought include
inherited breast cancer, intellectual disability, ataxia,
congenital sensory disorders, and inherited muscle dis-
orders.10 Over the past decade, molecular understand-
ing of the congenital muscular dystrophies (CMDs) has
greatly expanded.18 Congenital muscular dystrophy dis-
orders can be classified into four major groups, based on
the affected genes and the location of their expressed
protein: i) abnormalities of extracellular matrix proteins
(LAMA2, COL6A1, COL6A2, and COL6A3); ii) abnormali-
ties of membrane receptors for the extracellular matrix
(FKTN, POMGNT1, POMT1, POMT2, FKRP, LARGE,
ITGA7, and DAG1); iii) abnormal endoplasmic reticulum
protein (SEPN1); and iv) intranuclear envelope protein
(LMNA).19 Inheritance patterns range from classic auto-
somal recessive to de novo dominantly acting mutations
(COL6 and LMNA). A specific diagnosis can be challeng-
ing because muscle pathology may not yield a definitive
diagnosis, and access to and expertise in using immu-
nohistochemical stains is limited. Muscle biopsy and ge-
netic test findings must be interpreted in a clinical con-
text, yet the majority of diagnostic testing is not
accompanied by a standard clinical data set. When clin-
ical features are manifested in patients and recognized
by clinicians, the proportion of people who have the dis-
ease who test positive (clinical sensitivity) for merosin-
deficient, Ullrich/Bethlem, and Walker-Warburg syn-
drome CMDs and related CMDs is 100%, 60% to 65%,
and 60% to 65%, respectively.20 Mutation screening by
conventional Sanger-based DNA sequencing is not a
scalable technology in a clinical laboratory setting be-
cause of the time requirements to complete an analysis
and quality assurance procedures that exponentially in-
crease with genetic complexity.10
The goal of this study was to evaluate the RDT and SS
sequence enrichment technologies in conjunction with
NGS sequencing by comparing them to each other and
to the current gold standard, Sanger sequencing. We
selected 12 genes associated with CMDs, which span a
65-kb exonic region (321 exons  50 bp on either side of
each intron/exon boundary), as the clinical target in this
pilot study. Given the genetic complexity and the fact that
a specific diagnosis can be challenging, the genes thatmake up our CMD panel are ideal for evaluating the
effectiveness of these target enrichment methods for clin-
ical applications. In this report, we describe the identifi-
cation of sequence variants in 12 CMD genes using two
target enrichment methods (RDT and SS) and an NGS
sequencing platform (SOLiD 3; Life Technologies, Grand
Island, NY) under optimized conditions, and we discuss
our findings in light of the validation and clinical labora-
tory implementation of these enrichment approaches.
Materials and Methods
Patients
All development was performed at the Emory Genetics
Laboratory, which is a Clinical Laboratory Improvement
Amendments and College of American Pathologists–ac-
credited high-complexity laboratory. To demonstrate that
NGS data could be used to identify different types of
mutations, five positive control samples (C11, C12, C13,
C14, and C15) whose mutations had previously been
identified by Sanger sequencing of CMD panel genes
were included in the analysis. The CMD comprehensive
panel that consisted of Sanger sequencing COL6A1,
COL6A2, COL6A3, FKRP, FKTN, ITGA7, LAMA2, LARGE,
POMGNT1, POMT1, POMT2, and SEPN1 was performed
on sample C12. The Bethlem Myopathy/Ullrich CMD se-
quencing panel was performed (Sanger sequencing of
COL6A1, COL6A2, and COL6A3) on samples C11 and
C13. Moreover, the merosin-deficient CMD Type 1A
(MDC1A) sequencing panel (Sanger sequencing of
LAMA2) was performed on sample C14. Similarly, the
muscle-eye-brain disease sequencing panel was per-
formed (Sanger sequencing of POMGNT1) on sample
C15. Furthermore, a normal control sample (wild-type,
W16) known to lack any mutations was added to the
sample list.
In addition to the six control samples, six patients with
CMD phenotypes were selected from the cohort of fam-
ilies collected by Dr. Carsten Bonnemann (National Insti-
tutes of Health, Bethesda, MD) under an approved insti-
tutional review board from the Children’s Hospital of
Philadelphia, and written informed consent was obtained
for all patients. In all families, the affected members suf-
fered from an underlying muscular dystrophy. The under-
lying gene mutations had not been identified for three
patients, whereas the mutations were known for three
patients, and these represented our blinded sample set.
Microdroplet-Based PCR Primer Design
A list of the 12 CMD genes was provided to RainDance
Technologies (Lexington, MA), and they designed a cus-
tom CMD panel using their custom primer design pipe-
line based on the Primer3 algorithm (http://frodo.wi.mit.
edu/primer3). The custom panel was prepared, and
primers were designed to target all 321 coding exons
(383 amplicons) of these 12 genes, including 50 bp of
intronic sequence flanking each exon in the design. The
amplicons in the panel ranged in size from 200 to 600
bases, with a GC content of 25% to 87%, and repre-
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cleotide polymorphisms (SNPs) and repeat regions were
filtered from the primer selection region. The RDT design
was quality checked in our laboratory to ensure that none
of the primers were designed over known SNPs (dbSNP
build 130) using an in-house Perl script against the Na-
tional Center for Biotechnology Information SNP data-
base. Primers were also verified to avoid repetitive re-
gions of the genome using the program RepeatMasker
(http://www.repeatmasker.org). The primers for the 383
amplicons varied in annealing temperature from 57°C to
60°C, with a primer length range of 15 to 22 bases. Other
rules for primer design included BLASTing the primers to
the chromosome that had the gene of interest and in
silico PCR, using the UCSC Genome Browser, to match
the designed primers to the PCR product sequence and
size for the gene of interest.
Microdroplet-Based PCR
The samples were fragmented to 3 to 4 kb by shearing
the genomic DNA with the Covaris S2 instrument (Cova-
ris, Woburn, MA) following the manufacturer’s instruc-
tions. To prepare the input DNA template mixture for
targeted amplification, 3 g of the purified genomic DNA
fragments were added to 4.7 L of High-Fidelity buffer
(Invitrogen, Carlsbad, CA), 1.26 L of magnesium sulfate
(Invitrogen), 1.6 L of 10 mmol/L dNTP (Invitrogen), 3.6
L of 4 mol/L betaine (Sigma-Aldrich, St. Louis, MO), 3.6
L of Droplet Stabilizer (RainDance Technologies, Lex-
ington, MA), 1.8 L of dimethyl sulfoxide (Sigma-Aldrich),
and 0.7 L of 5 units/L of Platinum High-Fidelity Taq
(Invitrogen). The samples were brought to a final volume
of 25 L with nuclease-free water. PCR droplets were
generated on the RDT1000 instrument (RainDance Tech-
nologies). The CMD panel consists of an emulsion that
contains a collection of unique primer droplets in which
each primer droplet contains a single matched forward
and reverse primer for each amplicon in the panel. Each
panel contains multiple replicates of each unique primer
droplet. Careful control is achieved in the manufacture of
each panel to ensure that the volume of each droplet is
consistent. This ensures that the concentration of the
forward and reverse primers are consistent across all
PCR reactions. Furthermore, the manufacture of each
panel allows the counting of each unique primer droplet
so that the representation of each unique primer droplet
is consistent within the panel. This ability to uniformly
represent each primer droplet within each panel allows a
uniform representation of each PCR reaction per sample,
resulting in low bias between all of the amplicons in the
panel. The RDT1000 generates a PCR droplet by pairing
a single genomic DNA template droplet with a single
primer droplet. The paired droplets flow past an elec-
trode that is embedded in the chip and are instantly
merged to create a single PCR droplet. All of the resulting
PCR droplets are dispensed as an emulsion into a PCR
tube and then transferred to a standard thermal cycler for
PCR amplification. Each single sample generates more
than 1,000,000 singleplex PCR droplets. Samples were
cycled in an Applied Biosystems (Foster City, CA) Gene-Amp 9700 thermocycler as follows: initial denaturation at
94°C for 2 minutes; 55 cycles at 94°C for 15 seconds,
54°C for 15 seconds, 68°C for 30 seconds; final exten-
sion at 68°C for 10 minutes, and a 4°C hold. After PCR
amplification, the emulsion was broken to release each
individual amplicon from the PCR droplets. For each
sample, an equal volume of Droplet Destabilizer (Rain-
Dance Technologies) was added to the emulsion of PCR
droplets, the sample was vortexed for 15 seconds, and
spun in a microcentrifuge at 13,000  g for 5 minutes.
The oil below the aqueous phase was carefully removed
from the sample. The remaining sample was purified
using a MinElute column (Qiagen, Valencia, CA) following
the manufacturer’s recommended protocol. The purified
amplicon DNA was then tested on an Agilent Bioanalyzer
(Agilent Technologies, Santa Clara, CA) to confirm that
the amplicon profile (mixture of all amplicons of sizes
ranging from 200 to 929 bp) matched the expected am-
plicon profile.
Microdroplet-Based PCR Amplicon
Concatenation and Shearing
The ends of the amplicons were blunt-end repaired by
adding the reagents to the purified DNA (diluted to 68
L): 10 L of 10 blunting buffer (Epicenter, Madison,
WI), 10 L of 2.5 mmol/L dNTP Mix (Invitrogen), 10 L of
10 mmol/L ATP, 2 L of End-It enzyme mix (Epicenter,
Madison, WI), and sterile water to a total reaction volume
of 100 L. The reaction was incubated at room temper-
ature for 30 minutes, and the DNA was immediately pu-
rified using Ampure XP beads (Agencourt, Danvers, MA).
The amplicons were subsequently concatenated using
the NEB Quick Ligation kit according to the manufactur-
er’s protocol. DNA was purified using Ampure XP beads
and eluted in 105 L of low TE buffer. An Agilent Tech-
nologies 7500 Bioanalyzer chip was run to confirm the
concatenation of PCR products. The sample was frag-
mented as described in the standard SOLiD workflow.
SureSelect Probe Design and Synthesis
The biotinylated-cRNA probe solution was manufactured
by Agilent Technologies and was provided as capture
probes. The sequences corresponding to the 12 CMD
genes (321 exons) were uploaded to the Web-based
probe design tool, eArray.21 The coordinates of the se-
quence data in this study are based on NCBI Build 36.1
(UCSC hg18). The following parameters were chosen for
the probe design: 120-bp capture-probe length, 20
capture-probe tiling frequency, a 20-bp allowed overlap,
and avoidance of repetitive regions. In total, 54,420
probes were designed, synthesized on a wafer, subse-
quently released off the solid support by a selective
chemical reaction, PCR-amplified through universal prim-
ers attached on the probes, and then amplified and bio-
tin-conjugated by in vitro transcription.16
ogies; R
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Genomic DNA fragment libraries were prepared accord-
ing to the manufacturer’s instructions (Agilent Technolo-
gies). Briefly, 3 g of each genomic DNA was frag-
mented by Adaptive Focused Acoustics (Covaris S2;
Covaris), resulting in fragmentation of the genomic DNA
to a size range of 150 to 180 bp. After end repair, the
SOLiD barcoding adaptors were ligated and the libraries
cleaned up using Ampure XP beads. A high-sensitivity
bioanalyzer chip was run to ensure that ligation was suc-
cessful. Each fragment library was nick-translated and
enriched by a PCR amplification step. The PCR-amplified
fragment libraries were quantified by a NanoDrop
(ND1000; NanoDrop Technologies, Wilmington, DE).
SureSelect Solution-Based Hybridization and
Target Enrichment
The target-enrichment step for each sample was per-
formed according to the manufacturer’s instructions (Agi-
lent Technologies). Briefly, in a 96-well PCR plate, the
capture probes were mixed with RNase block solution
and kept on ice in a separate PCR plate; 500 ng of each
genomic DNA-fragment library (“B” row) was mixed with
SureSelect Block Mix and transferred into the B row,
heated for 5 minutes at 95°C, and held at 65°C thereafter
in the thermocycler GeneAmp PCR System 9700 thermo-
cycler (Applied Biosystems). While maintaining the plate
Table 1. Mapping Data of Reads Obtained Following Sequence
Patient no.
Targeted
method
High-quality reads
(n)
Mapped to
human genom
(%)
C11 RDT 209,312 57
SS 456,576 60
C12 RDT 338,596 57
SS 589,792 57
C13 RDT 265,206 56
SS 585,719 55
C14 RDT 162,715 53
SS 364,716 48
C15 RDT 343,911 55
SS 408,524 56
W16 RDT 482,435 57
SS 358,043 60
1 RDT 461,154 53
SS 219,550 51
3 RDT 526,152 55
SS 533,999 54
7 RDT 328,037 51
SS 536,653 53
8 RDT 558,078 55
SS 433,943 58
9 RDT 237,236 43
SS 223,520 46
10 RDT 712,674 54
SS 325,952 56
Ave.  SD RDT 385,459  164,064 54  4
Ave.  SD SS 419,749  127,594 55  4
Reads were obtained from RainDance Technologies and SureSelect
dystrophy target regions using a SOLiD sequencing platform.
Ave., average; C, positive control samples; RDT, RainDance Technolat 65°C, hybridization buffer was added into the “A” rowof the PCR plate and incubated at this temperature for at
least 5 minutes. The capture library mix was added to the
“C” row in the PCR plate and incubated for 2 minutes at
65°C. The hybridization mixture was added to the capture
probes, followed by the addition of the DNA fragment
library. The solution hybridization was performed for 24
hours at 65°C.
After the hybridization, the captured targets were se-
lected by pulling down the biotinylated probe/target hy-
brids by using streptavidin-coated magnetic beads (Dy-
nal DynaMag-2; Invitrogen). The magnetic beads were
Figure 1. Average gene coverage among all of the congenital muscular
ent
n target
(%)
Mean read
length,
(bases)
Bases covered
for ROI (5)
(%)
Bases covered
for ROI (20)
(%)
36 47 88 86
18 47 96 95
36 47 88 87
19 47 96 95
35 47 88 87
18 47 96 96
29 47 87 84
14 47 96 95
38 47 88 87
16 47 96 95
31 47 87 86
17 47 96 95
38 46 88 87
18 47 95 94
35 47 89 88
23 47 96 95
37 46 88 87
17 47 96 94
36 47 88 87
20 47 96 95
29 47 88 86
14 47 96 94
36 47 89 88
16 47 96 95
35 3 47  0 88 1 87  1
18 3 47  0 96 0 95  1
e enrichment of human genomic DNA samples for congenital muscular
OI, region of interest; SS, SureSelect; W, wild-type sample.Enrichm
e O
sequencdystrophy genes following RainDance and SureSelect target enrichment and
next-generation sequencing.
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ing buffer [1 mol/L NaCl, 1 mmol/L EDTA, and 10 mmol/L
Tris-HCl (pH 7.5)]. The captured target solution was
added to the beads and rotated for 30 minutes at room
temperature. The beads/captured targets were pulled
down by using a magnetic separator (DynaMag-Spin;
Invitrogen), removing the supernatant, resuspending in
wash buffer #1 (Agilent Technologies), and incubating for
15 minutes at room temperature. The beads/captured
probes were pulled down with the magnetic separator
and washed by resuspension and incubation for 10 min-
utes at 65°C in wash buffer #2. After three warm washes,
elution buffer (0.1 mol/L NaOH) was added and incu-
bated for 10 minutes at room temperature. The eluted
captured targets were transferred to a tube containing
neutralization buffer [1 mol/L Tris-HCl (pH 7.5)] and de-
salted with the MinElute PCR Purification Kit (Qiagen).
Finally, the targets were enriched by 20 to 30 cycles of
PCR amplification by using 5 L per sample as a tem-
plate, and the amplified targets were purified by Ampure
XP beads. The samples were processed by the standard
SOLiD workflow.
Variant Annotation and Identification of
Causative Mutations
SNP and indel information was extracted from the align-
ment data using the NextGENe (Softgenetics, State Col-
lege, PA) software. Analysis was limited to 20 bp on
either side of each exon. Additional custom filtering cri-
Table 2. Common and Unique Exons with Consistently Low Cov
RDT
Gene Exon # %GC Gene
COL6A1 5 65 LAMA2
COL6A1 12 67 SEPN1
COL6A1 24 68
COL6A1 30 59
COL6A1 34 50
COL6A1 35 67
COL6A2 3 65
COL6A2 6 65
COL6A2 7 64
COL6A2 14 68
COL6A2 16 71
COL6A2 22 73
COL6A2 24 63
COL6A2 26 62
COL6A2 27 59
COL6A3 13 48
COL6A3 15 63
FKTN 6 41
FKTN 7 45
ITGA7 15 62
ITGA7 25 66
LAMA2 27 36
LAMA2 47 43
POMT2 9 62
POMT2 10 40
SEPN1 6 87
Coverage was 20 average.
%GC, percent GC content.teria were imposed to minimize the false-positive rates.Variants were filtered first for those that are novel (not
present in dbSNP or the 1000 Genomes databases) and
for those that are likely deleterious. We predicted that
damaging SNPs would be novel silent, missense, non-
sense, or splice-site SNPs, whereas damaging indels
would be in coding regions. The variants that met these
criteria were used for downstream analysis. Specifically,
a large list of variants were identified by NGS; however,
variants with 20 coverage (coverage is the average
number of reads representing a given nucleotide in the
reconstructed sequence) were removed from the list to
be Sanger sequence confirmed, unless a variant was
listed in the Human Gene Mutation Database as a frame-
shift or a nonsense change. In addition, variants with high
frequency were also removed, but Human Gene Muta-
tion Database, frameshift, and nonsense changes were
kept. Similarly, synonymous coding variants previously
found in the normal population were removed from the
list. There were examples of variants in exons with
20 coverage that were selected for confirmation
based on the likelihood of being real changes as indi-
cated by the allele percentage (the percentage of a
nucleotide at a specific location given by NextGENe
visual sequence output; for a heterozygote and a ho-
mozygote, a 50%:50% and 90% allele percentage is
expected, respectively) and Phred-like sequencing
quality score (q), defined as q  10log10(p), where
p  error probability for the base (ie, if q  20 and P 
0.01, then the error rate is 1 in 100) at that site. Finally,
all variants that met all of the specified criteria were
across All RDT and SS Samples
RDT and SS
%GC Gene Exon # %GC
33 COL6A1 1 73
58 LAMA2 1 71
LAMA2 44 17
SEPN1 1 87
POMT1 2 60
POMT1 3 45
POMT1 4 39
POMT1 5 59
POMT1 6 40
POMT1 7 56
POMT1 8 57
POMT1 9 55
POMT1 10 59
POMT1 11 51
POMT1 12 67
POMT1 13 57
POMT1 14 49
POMT1 15 67
POMT1 16 64
POMT1 17 59
POMT1 18 57
POMT1 19 61
POMT1 20 55erage
SS
Exon #
53
3Sanger sequence confirmed.
se pos.
nic vari
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Primers were designed to amplify each exon, including
50 bp of flanking intronic regions of LAMA2, COL6A1,
COL6A2, COL6A3, FKTN, POMGNT1, POMT1, POMT2,
FKRP, LARGE, ITGA7, and SEPN1. Samples were pre-
pared by fluorescence sequencing on the ABI 3730XL
DNA analyzer with BigDye Terminator chemistry and
the BigDye XTerminator purification kit (Applied
Biosystems).
Results
A total of 12 samples were evaluated in this compara-
tive study. Five positive control samples were chosen
to have different types of CMD-causing mutations to
evaluate the ability of the target enrichment methods to
identify different types of sequence variations. In ad-
dition, a wild-type sample was included to serve as a
normal control reference. Moreover, six blinded sam-
ples were examined by NGS to identify the underlying
Table 3. Number of Sequence Variants Identified by RainDance
Positive Rates
Patient no.
Targeted
method
Total NGS
variants*
Variants m
by NGS
C11 RDT 8 (8) 7 (6)
SS 9 (16) 7 (6)
C12 RDT (53) (5)
SS (43) (5)
C13 RDT 6 (14) 5 (7)
SS 12 (19) 4 (2)
C14 RDT 7 (4) 15 (1)
SS 16 (7) 9 (0)
C15 RDT 20 (6) 11 (0)
SS 23 (4) 11 (0)
W16 RDT 21 12
SS 17 11
1 RDT 18 10
SS 16 9
3 RDT 15 6
SS 21 5
7 RDT 17 9
SS 22 6
8 RDT 24 6
SS 11 7
9 RDT 15 18
SS 20 15
10 RDT 20 8
SS 18 8
Ave.  SD RDT 16  6 (17  20) 10  4 (4
Ave.  SD SS 17  5 (18  15) 8  3 (3
The bold numbers indicate the sequence variants that were identified
filtered data to minimize the false-positive rates. The filtering criteria were
numbers in parentheses are the number of variants identified using unfilte
positive control samples only.
*Total number of variants identified following each enrichment method
†Total number of variants identified by Sanger sequencing and misse
and Methods.
‡Total number of variants identified by next-generation sequencing th
Ave., average; C, positive control samples; EX, exonic variants; Fal
variants; N-SNP EX, non-SNP exonic variants; N-SNP INT, non-SNP intromutation(s) responsible for the clinical features de-scribed for each patient and to evaluate each method
for its diagnostic potential.
RDT and SS Enrichment Strategies
Demonstrate Similar Sequencing Coverage and
Genome Mapping
A single run on the SOLiD produced a read average of
385,459 and 419,749 for RDT and SS, respectively, with
no statistically significant difference between the two en-
richment methods (Table 1). RDT and SS samples had a
similar average percentage mapped to the genome,
namely, 54% and 55%, respectively. However, on aver-
age, a higher percentage of the RDT reads mapped to
the target region relative to the SS reads. A range of 29%
to 38% of RDT and 14% to 23% of SS unique reads
mapped to the targeted regions, percentages that are
consistent with other studies.17,22 Approximately 96% of
the region of interest had at least a 5 coverage in the SS
samples compared to 88% of the RDT samples. Similarly,
95% of the region of interest had at least 20 coverage in
logies and SureSelect Using Filtered Data to Minimize the False-
Sanger
variants‡
False
positive (%)
No. of exons with
20 coverage
7 (5) (37) 94
7 (12) (25) 30
(39) (26) 93
(37) (30) 27
4 (12) (14) 87
5 (18) (5) 22
5 (4) (0) 186
9 (5) (13) 38
13 (4) (33) 92
12 (4) (0) 45
8 NA 106
10 NA 55
8 NA 76
7 NA 61
8 NA 79
9 NA 25
11 NA 94
10 NA 82
14 NA 74
12 NA 29
8 NA 146
10 NA 107
12 NA 65
13 NA 45
9  3 (13  15) (22  15) 100  36
9  2 (20  24) (15  13) 49  26
(table continues)
Dance Technologies and SureSelect next-generation sequencing using
d to RDT and SS data on the blinded and positive control samples. The
T and SS data to confirm previously identified Sanger method variants in
ext-generation sequencing.
GS because such data was filtered by the criteria described in Materials
confirmed by Sanger sequencing.
(%), false-positive percentage; INT, intronic variants; N-SNP, non-SNP
ants; W, wild-type normal sample.Techno
issed
†
 3)
 3)
by Rain
applie
red RD
and n
d by N
at werethe SS samples and lower in the RDT samples (87%).
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The target sequence complexity has a strong effect on
the efficiency of DNA amplification and capture for indi-
vidual exons. The mean gene depth was similar between
the RDT and SS samples (Figure 1). The mean gene
depth of coverage across all RDT samples ranged from
0 for POMT1, to 108 for POMGNT1, with an average of
51  28 across all genes. By contrast, the mean gene
depth of coverage across all SS samples ranged from 2
for POMT1, to 87 for LARGE, with an average of 53 
22 across all genes. In some instances, RDT enriched
certain genes, namely, POMGNT1 and POMT2, better
than SS (Figure 1). The opposite is also true: SS enriched
LARGE better than RDT.
Despite the high mean gene-read depth and target
region coverage, several exons, including exon 1 of
COL6A1, exon 1 of LAMA2, exon 1 of SEPN, and all exons
of POMT1, had low average coverage in both RDT and
SS runs (see Supplemental Figures S1–S4 at http://jmd.
amjpathol.org and Table 2). In addition, a closer exami-
nation showed that the first coding exons were poorly
Table 3. Continued
INT EX SNP
0 (3) 8 (5) 7 (6)
0 (3) 9 (13) 7 (12)
(17) (36) (44)
(24) (38) (41)
2 (5) 4 (9) 4 (12)
1 (7) 11 (12) 5 (15)
1 (3) 6 (1) 5 (4)
2 (3) 14 (4) 8 (4)
5 (1) 15 (5) 12 (2)
3 (1) 20 (3) 23 (2)
3 18 6
5 12 5
7 11 8
8 8 8
5 10 12
5 16 13
5 12 8
5 18 10
8 16 11
9 18 12
3 12 8
3 17 11
7 13 13
7 11 12
4  3 (6  6) 11  4 (11  14) 9  3 (14  17
4  3 (8  9) 14  4 (14  14) 10  515  16covered (see Supplemental Figures S1–S12 at http://jmd.amjpathol.org). All of the exons of POMT1 failed due to
the average percent GC content of 56%, and several exons
have a percent GC content 60%. Interestingly, 26 exons
of the 321 targeted exons (8%) had low coverage in RDT
compared to 2 exons (0.8%) in SS samples (Table 2).
Variant and Mutation Identification in Control
Samples
The Sanger method is considered by the clinical labora-
tory community as the gold standard for sequencing. To
validate the enrichment methods, we compared the vari-
ant calls obtained by Sanger sequencing to those ob-
tained by NGS using five control samples with known
mutations and one wild-type normal control as follows:
1. Sample C11: COL6A1, COL6A2, and COL6A3 se-
quenced for Bethlem myopathy/Ullrich CMD panel;
2. Sample C12: LAMA2, COL6A1, COL6A2, COL6A3,
FKTN, POMGNT1, POMT1, POMT2, FKRP, LARGE,
and ITGA were sequenced for CMD comprehensive
panel;
3. Sample C13: COL6A1, COL6A2, and COL6A3 were
N-SNP N-SNP INT N-SNP EX
1 (2) 0 (0) 1 (2)
2 (4) 0 (0) 2 (4)
(9) (3) (6)
(21) (8) (13)
2 (2) 1 (0) 1 (2)
7 (4) 0 (1) 7 (3)
2 (0) 0 (0) 2 (0)
6 (3) 0 (0) 6 (3)
8 (4) 2 (1) 6 (3)
7 (2) 0 (1) 10 (1)
15 2 13
12 4 8
10 4 6
8 6 2
3 2 1
8 1 7
9 1 8
12 0 12
13 4 9
15 27 4
7 1 6
9 0 9
7 1 6
6 1 5
7  5 (4  3) 2  1 (1  1) 5  4 (3  2)
8  4 (7  8) 4  8 (2  3) 7  3 (5  5))sequenced for Bethlem myopathy/Ullrich CMD panel;
ignifica
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panel;
5. Sample C15: POMGNT1 was sequenced for the
muscle-eye-brain panel;
6. Sample W16: wild-type control.
Different sets of genes were sequenced for the control
samples because, traditionally, the clinical features of the
patients were used to determine which genes should be
pursued. Specifically, we sequenced the five positive
controls, which encompass a variety of variants, such as
deletions (sample C14), duplications (samples C12 and
C13), missense (sample C11), and splicing changes
(sample C15), post-RDT or SS enrichment using the
SOLiD platform and the Sanger method (Table 3).
NGS identified a large number of sequence variants
within our targeted regions of the controls with 100%
concordance to Sanger sequencing results (Table 3).
Table 4. Detection of Variants and Mutations Following Target E
Patient
no. Gene
Exon/
intron Muta
C11 COL6A1 30 c.1931G
COL6A2 23 c.1770G
COL6A2 28 c.2994C
C12 COL6A1 29 IVS29-8G
FKTN 9 IVS9-40C
LAMA2 14 c.2084C
LAMA2 39 c.5614G
SEPN1 5 IVS539
SEPN1 11 IVS11-31
SEPN1 13 c.1645G
SEPN1 3=UTR c.1773
C13 COL6A1 26 IVS265
COL6A1 33 c.2424G
COL6A2 24 IVS24-3d
COL6A3 38 IVS38-34
C14 LAMA2 22 c.3154A
LAMA2 47 c.6617de
C15 POMGNT1 7 c.636C
POMGNT1 17 IVS171
W16
1 COL6A3 14 IVS14-8d
3 COL6A2 22 IVS224
LAMA2 27 c.4010A
7 COL6A3 1 c.53CA
8 COL6A1 6 IVS6-18C
LAMA2 24 c.3412G
LAMA2 43 IVS435
9 COL6A1 21 IVS21-2A
COL6A2 26 c.2039G
COL6A2 22 IVS224
COL6A3 41 c.9206C
LARGE 15 c.1949G
SEPN1 12 c.1506C
10 COL6A1 14 IVS141
Target enrichment achieved by RainDance Technologies and Sure
mutation predicted to result in a premature translation stop. This change
*It is possible for silent changes to disrupt RNA splicing.
†Mutation and/or variant of unknown clinical significance not detected
boundaries.
‡This mutation has been reported in individuals with MEB disease.
§This mutation results in a G to A change in the consensus donor site
of POMGNT1 RNA. This mutation has been reported in individuals with M
, present; , not present; C, positive control samples; Del, deletion; H
Mut, mutation; UTR, untranslated region; VUS, variant of unknown clinical sThe NGS-identified variants of the positive control sam-ples were generated by using the unfiltered RDT and SS
data, so that it would be a true variant number compari-
son between the enrichment methods and Sanger se-
quencing. After a close examination of parameters such
as coverage, allele percentage, and Phred-like score, the
false-positive rate (Table 3) decreased significantly by
eliminating variant calls with low probability of being true
positives. On average, the false-positive rate of the two
methods, RDT (22%  15%) and SS (15%  13%), was
not statistically different. However, in several cases, the
RDT false-positive rate was lower than the SS rate, such
as in sample C14. By contrast, false-negative variants not
detected by the RDT NGS were often in exons with poor
sequence coverage (20) and high GC content. For
example, exon 22: IVS224GA, change in COL6A2
was not observed using the RDT data due to 0 cover-
age and 73% GC content (Tables 2 and 4). However, this
ent
Amino acid change/
consequence (frameshift/del)
Status
(Homo/Het)
p.R644Q Het
p.T590 Het
p.H998 Het
Het
Het
p.D695V Het
p.D1872Y Het
Het
Het
p.V549M Het
Het
Het
p.Q808H Het
Het
Homo
p.S1052G Het
frameshift Het
p.F212 Het
Het
Del Het
Het
p.H1337R Het
p.A18X Homo
Het
p.V1138M Het
Het
Het
p.R680H Het
Het
T3069I Het
p.R650Q Het
p.N502K Homo
Het
(table continues)
n combination with next-generation sequencing. Out-of-frame deletion
e type predicted to cause disease.
se the bioinformative algorithm set to detect 20 bases from exon/intron
xon 17/intron 17 boundary and is predicted to result in aberrant splicing
ease.
rozygous change; Homo, homozygous change; MEB, muscle-eye-brain;
nce, pending functional analysis for reclassification; W, wild-type sample.nrichm
tion
A
A
T
A
A
T
T
CT
CT
A
44GT
0CT
T
upC
CT
G
lT
T
GA
el29
GA
G
CT
A
GC
G
A
GA
T
A
A
GA
Select i
is of th
becau
of the e
EB dis
et, hetechange was confirmed by Sanger sequencing.
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ficity render target enrichment methods suitable for the
reliable detection of different types of sequence variants
in positive control samples. RDT and SS in combination
with NGS correctly identified most variants of unknown
clinical significance and mutations in the positive control
samples (C11 to C15), except for changes whose cover-
age was too low (Table 4 and Figure 2, A and B). Deep
intronic variants were not detected because we limited
the custom set of sequence analysis to 20 bp on either
side of each exon. Examples of mutations detected by all
three methods include a POMGNT1splice site change in
sample C15, one copy of IVS171GA in intron 17 (Fig-
ure 2A and Table 4), and a missense change detected in
sample C12 LAMA2, one copy of c.2084CT (p.D695V)
in exon 14 (Figure 2B). By contrast, changes that were
found in one data set but not the other include:
c.1931GA (p.R644Q) in IVS24-3dupC in COL6A1 and
Table 4. Continued
RDT
detected
RDT mutation
coverage
SS
detected
 11 
 8 
 20 
 7 
  
 82 
 29 
  
  
 78 
  
  
 8 
 8 
  
 17 
 1 
 34 
 105 
 87 
 44 
 10 
 111 
 66 
 66 
 66 
  
 8 
  
 26 
 10 
 26 
 19 c.6617delT in LAMA2 not detected in RDT samplesC11 and C14, respectively, but that were found in the
corresponding SS samples. Conversely, one change,
c.1770GA (p.T590) in exon 23 of COL6A2, was iden-
tified in the RDT data of sample C11, but not in the SS
data of the same sample. The missed changes in the
RDT data may be explained by the coverage being too
low at these sites, which is a likely consequence of
high GC content.
Variant Types Detected by NGS in Blinded
Samples
RDT and SS in combination with NGS permitted the de-
tection of different types of variants in the six blinded
control samples, and a significant proportion of such
variants were confirmed by Sanger sequencing (Table 3;
see Materials and Methods for filtering data criteria). The
mutation
verage
Sanger
confirmed Notes
66  VUS
20  VUS*
42  VUS*
34  VUS
  VUS†
63  VUS
88  VUS
  VUS†
  VUS†
159  VUS
  VUS†
  VUS†
17  VUS
162  VUS
  VUS†
40  VUS
75  Del mut
30  Splicing mut‡
73  Splicing mut§
  Del mut
137 
32  Possibly damaging
35  Nonsense mut
122 
132  Mut-HGMD
15 
 
22 
26 
15 
49 
17 
14  Splicing mutSS
cotypes of identified variants were exonic and intronic vari-
12. One
utation
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sense, deletion, nonsense, splice site alteration, and du-
plication changes that we found in our data are
c.4010AG (p.H1337R) in LAMA2 (sample 3), IVS14-
8del29) in COL6A3 (sample 1), c.53CA (p.A18X) in
Figure 2. Types of variants detected in RainDance and SureSelect samples
C15. One copy of an IVS171GA splice site mutation in intron 17 of POMG
splice site mutation. B: Example of missense mutation detected in sample C
in Sanger sequencing, RainDance, and SureSelect data. Arrows, missense m
Table 5. A comparison of Two Enrichment Methodologies, Rain
Standard, the Sanger Method
Parameters RainDance Technologies
Clinical implementation Yes
Cost per PCR amplicon $1.56
Equipment Use of specialized equipment,
automation
Ease of use Easier, small number of steps
DNA requirement 3 g for 1 Mb target
Length of region for
enrichment
Up to 1 Mb
Scalability (samples/day) One patient per time
(8 samples/day)
Variant calls 20 coverage needed
Limitation May be used for genes with
pseudogenes
Analytical sensitivity 85% (95% CI: 72–88%)
Analytical specificity 99.5% (95% CI:
99.9%–100%)
Uniformity 85% uniform amplification
Reproducibility 99% reproducibility at 10-fold
between two samples
*The specificity variation depends on which exons are captured in a
Therefore, RainDance Technologies amplifications are more reproducibl
†The average exon coverage profile of each gene varies between SureSelect c
coverage profile is much more consistent.COL6A3 (sample 7), IVS141GA in COL6A1 (sample
10), and IVS24-3dupC in COL6A2 (sample C14). The total
number of RDT variant calls in the blinded control sam-
ples varied from 6 to 24, and approximately 60% of the
calls were Sanger sequence confirmed. Similarly, SS
e Sanger sequence confirmed. A: Example of splice site mutation of sample
s detected by Sanger sequencing, RainDance, and SureSelect data. Arrows,
copy of c.2084CT (p.D695V) missense mutation in LAMA2 was observed
.
Technologies and SureSelect, Relative to the Sequencing Gold
SureSelect Sanger
Yes
$5.48
f specialized equipment,
omation or manual
cution
None required
licated, many
ipulations
Labor intensive
for up to 30 Mb target 19 g for 65 Kb region
exome Most limited
patients per time
amples/day)
One exon per time (1 sample/
day)
coverage needed 2
t be used for
udogenes
May be used for genes with
pseudogenes
(95% CI: 77%–91%) 99.5% (95% CI:
95.6%–100%)
.5%* (95% CI: 79.9%–
%)
99.5% (95% CI:
99.9%–100%)
uniformity capture 95% uniform amplification
reproducibility at 10-fold
ween two samples†
100% reproducibility at 2-fold
between two samples
experiment. Exon capture variability has been observed in SureSelect.
ureSelect captures.that wer
NT1 waDance
Yes
$2.34
Use o
aut
exe
Comp
man
3 g
Up to
Eight
(8 s
20
Canno
pse
85%
85–99
99.9
85%
85%
bet
given
e than Sapture experiments, whereas the RainDance Technologies average exon
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60% were also Sanger sequence confirmed. On average,
10 and 8 variants were not detected in the RDT and SS
data, respectively. Many of these variants were in prob-
lematic regions that had low exon coverage due to the
high GC content, as indicated by the number of exons
with 20 coverage (Tables 2 and 3). In general, NGS
successfully identified silent, missense, nonsense, splice
site, deletion, and duplication changes in positive and
blinded samples using RDT and SS data. Deletions of up
to 30 bp have been detected by NGS.
Comparison of Enrichment Methods
Comparison of the RDT and SS enrichment methods for
SOLiD sequencing, and Sanger sequencing demon-
strated essential similarities and differences (Table 5).
RDT offers the lowest cost per amplicon, which is signif-
icantly less than SS and Sanger sequencing. Though
RDT requires specialized equipment for the enrichment,
its advantage is the ability to offer automation for the
enrichment process. In addition, the DNA requirement for
a 65-kb target interval is 3 g for RDT and SS, but it is
much higher for Sanger sequencing (19 g). RDT is
much better than Sanger sequencing in terms of being
able to process more samples per day (eight vs. one).
The RDT throughput is similar to that of SS; however, the
enrichment step of the RDT process is automated. Re-
cently, the automated Agilent NGS Sample Preparation
Workstation was developed to streamline the sample
preparation of the targeted next-generation sequencing
workflow, which greatly improves the throughput and re-
duces the hands-on time. RDT also has the advantage
over SS in its ability to distinguish between a gene and its
pseudogene targets during the enrichment process.
The analytical sensitivities of RDT and SS (85%) are
similar to each other, but lower than Sanger sequencing
(99.5%) (Table 5), whereas the analytical specificities
of RDT and Sanger (99.5%) sequencing is similar, but
lower for SS (85% to 95.5%). RDT and Sanger displayed
significantly higher reproducibility than SS. When two
samples are compared to each other, the RDT data
demonstrated 99% variant call identity, and SS was
lower at 85%.
Discussion
In recent years, studies have shown that target enrich-
ment in combination with NGS holds out the promise of
becoming a useful diagnostic tool for the detection of
mutations in families with complex monogenic disor-
ders10,23–26; however, the performance of this technology
has to be addressed before implementing it in a clinical
and diagnostic laboratory setting. Here, we evaluate
strengths and limitations, including the ability to identify
different types of sequence variations and the diagnostic
potential, of two enrichment technologies, RDT and SS, in
a cohort of patients presenting with congenital muscular
dystrophies, a clinical classification with heterogeneous
genetic causes (Tables 1 and 3, numbers in parentheses;Table 3, bold numbers). To this end, a wild-type control,
which had all 12 CMD genes Sanger sequenced, was in-
cluded to serve as a normal control reference, along with
five positive control samples blinded to laboratory staff and
six blinded samples with clinical features of the CMDs.
The percentage of reads successfully mapped to the
human genome was similar between RDT and SS, but a
higher percentage of RDT reads mapped to the target
region in comparison to the SS reads (Table 1). The
target region–mapped percentages are consistent with
other reports.1,17,22,27 Thus, this demonstrates that spec-
ificity is lower in SS samples. The off-target reads in RDT
samples may be explained by nonspecific sequence am-
plification and contaminating traces of genomic DNA.
High specificity and uniformity has been shown for RDT
between different amplicons by a study that was investi-
gating new disease-causing mutations in X-linked intel-
lectual disability genes.1 Compared to other hybridization
methods, RDT is better suited for enriching for short
neighboring exons.1 PCR can be optimized to amplify
target regions, whereas hybridization approaches will
have to carry adjacent sequences together with real
ones, thereby reducing specificity and lowering target
percentages (Table 1). In addition to its specificity, RDT
has less allelic bias, since most alleles can be equally
amplified. For a simple two-allele example, the ability to
see both alleles is attributed to the ability of RDT to
represent less than a haploid copy of the genome within
each PCR reaction. This results in RDT having the ability
to achieve single-molecule PCR, which is not possible
with any other target enrichment strategy, including other
PCR-based approaches. The result of having limiting
amounts of genomic DNA is that when an allele is rare,
RDT will have many singleplex PCR reactions per ampli-
con, allowing the rare allele to be present within one PCR
reaction in which it is represented as the only target,
letting us mitigate allelic competition. In contrast, selec-
tion by hybridization will capture less of an allele that is
significantly different from the reference, and this allelic
bias can increase false-negative rates.1 Moreover, the
target mapped reads are lower in the SS samples
compared with the RDT samples, because there may
be other 100% identical matches to off-target regions
on other chromosomes, which resulted in the reads to
these exons not being mapped by the read alignment
programs.22
The target sequence complexity has a strong effect on
the efficiency of DNA amplification and capture for indi-
vidual exons. Even though the mean gene coverage/read
depth was similar within and between RDT and SS sam-
ples, all exons of POMT1 were not amplified by RDT or
captured by SS, and thus a low coverage was observed
(Figure 1). Generally, a high mean gene read depth was
observed for most exons of most genes, with the excep-
tion of POMT1. However, in many samples, the first exon
was problematic and typically had a low average cover-
age in both RDT and SS runs (see Supplemental Figures
S1–S12 at http://jmd.amjpathol.org and Table 2). High GC
content may explain the low coverage in the first exons of
genes, given that the mean GC content of the first coding
exon of all CMD genes is 64%. Also, the exons of POMT1
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failed exons have a percent GC content 60% (Table 2).
For example, exon 1 of SEPN1, COL6A1, and LAMA2 had
the highest GC contents, with percentages of 87, 73, and
71, respectively (Table 2). In addition, most exons that
dropped out in the RDT samples also had a high GC
content, which may hinder PCR amplification and could
explain the absence of sequence data and lack of variant
calls in these regions. Moreover, the negative effect of
high GC content, as seen in our study for the exons with
very low or null coverage, is also consistent with previous
reports.1,22,28 In contrast to RDT, SS is also sensitive to
sample base composition, and sequences at the ex-
tremes of high GC/AT content can be lost through poor
annealing and secondary structure, respectively.28 An-
other consideration is that it is seldom possible to capture
all of a desired target region in a hybrid capture experi-
ment; targets are generally subjected to repeat masking
(seeMaterials and Methods) before probe design to avoid
capture of homologous repetitive elements. For exonic
targets, 5% to 15% of the primary target region can be
lost in this way, leaving a region to which probes could be
designed after repeat masking, or target capture region,
that constitutes 85% to 95% of the primary target re-
gion. For contiguous regions, the percentage of primary
target region that is represented in the capture target
region is generally lower (50% to 65%), but this is highly
variable between regions (Table 1).
Relative to RDT, SS capture–based enrichment had a
smaller number of missed exons, which may be ex-
plained by our use of 120-bp probes due to their length
and the 20 tiling redundancy that ensured capturing a
target even if another probe missed it. The tiling redun-
dancy would not be an advantage if larger genomic re-
gions were to be targeted, since the most probes allowed
is 55,000 per design. This means that RDT and SS en-
richment technologies both have the potential for clinical
use; however, Sanger sequencing will still be needed to
confirm complex exons that are inefficiently amplified or
captured. At this time, diagnostic applications of enrich-
ment methods with NGS are complementary to Sanger
sequencing efforts until they achieve high enough cover-
age to account for all possible variants at a given target
region.
Allelic dropout due to SNPs in the PCR primer binding
sites is a limitation inherent to all PCR-based assays,
including Sanger sequencing.29 RDT uses a library of
primers to amplify the target regions and is therefore also
susceptible to allele dropout if specific SNPs are in the
primer binding sites. To minimize the absence of ampli-
fication of specific exons due to allele dropout, primers
were designed in regions where SNPs have not been
reported by using the Single Nucleotide Polymorphism
and the 1000 Genomes databases. In the event that allele
dropout occurs in RDT-targeted exons, sequence cover-
age cannot overcome allele dropout because there will
be an absence of amplification, and such products con-
sequently would generate zero to low sequence reads.
By contrast, SS is a hybridization-based technology that
relies on 120-bp probes to capture the region of interest.
In this case, SS is likely to be less susceptible to alleledropout, meaning that a particular exon of interest will not
be captured, because one SNP out of 120 bp may not be
enough to affect the binding of the SS probe to its target.
Also, to further decrease the chance for allele dropout, a
20 capture-probe tiling frequency and a 20-bp allowed
overlap was used in the probe design. Even though the
likelihood of allele dropout happening in an SS experi-
ment is low, it is possible that the probes will not capture
the targets of interest. Sequence coverage cannot over-
come allele dropout, because no targets would be avail-
able to sequence. Although both technologies may be
susceptible to allele dropout, the aforementioned consid-
erations were taken into account to minimize such events.
Furthermore, the importance of noting the clinical pheno-
type in the diagnosis of patients should be kept in mind to
decrease the false-negative cases even further.
In assessing the validity of variants identified by NGS
following RDT and SS enrichment, we saw that there was
a deviation of NGS-identified variants in the targeted re-
gions relative to Sanger sequencing results (Table 3).
The analytical sensitivity of RDT and SS was lower than
that of Sanger sequencing: 85%, 85%, and 99.5%,
respectively (Tables 4 and 5). However, in positive con-
trol samples, RDT in combination with SS data was suf-
ficient to correctly identify most variants of unknown clin-
ical significance and mutations, with the exception of
deep intronic variants and variants whose coverage was
too low (Figure 2, A and B, and Table 4). The false-
positive rates, possibly caused by inefficiency of ampli-
fication and artifacts of sequencing, decreased after in-
vestigators learned that the coverage levels, allele
percentages, and Phred-like scores in combination were
necessary to reach a threshold of 15% (Table 3).
NGS permitted different types of variants to be de-
tected following RDT and SS enrichment in the six
blinded control samples, including silent, missense, non-
sense, small deletion, and small duplication changes
(confirmed by Sanger sequencing; Table 4). The range of
the total number of RDT variants was between 6 and 24,
compared with SS variant calls of 9 to 23. However, on
average, approximately 60% of such variants were con-
firmed by Sanger sequencing because of low exon cov-
erage in some regions, as indicated by the number of
exons with 20 coverage (Tables 2 and 3).
Several parameters are worth comparing between the
two enrichment technologies and contrasting them to
Sanger sequencing; namely, clinical implementation,
cost, requirement for specialized equipment, ease of use,
analytical sensitivity and specificity, and scalability (Ta-
ble 5). RDT offers the lowest enrichment cost per ampli-
con when compared to SS and Sanger sequencing. An
advantage of RDT requiring specialized equipment for
the enrichment is that it allows full enrichment automation.
By contrast, the manual SS procedure is more compli-
cated and Sanger sequencing is labor intensive, since
one must amplify and sequence each amplicon. How-
ever, an automated platform is now available for the SS
enrichment method to fully automate the library construc-
tion steps. The RDT and SS DNA requirements are sim-
ilar, but the Sanger method requires a significantly higher
amount of DNA. RDT is more appropriate for situations
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enrich a target interval up to 1 Mb. Up to eight samples
can be processed per day. Similarly, SS can be used to
process eight patients per day, but it can enrich a much
larger target interval, up to the entire exome. By contrast,
only one patient sample may be processed by Sanger
sequencing in a day because it is such a large panel (383
amplicons). One important diagnostic issue is the ability
to distinguish between gene and pseudogene targets;
RDT and Sanger can readily address this issue by cor-
rectly choosing locations where the primers are to hybrid-
ize on the genomic DNA template. Since SS is a hybrid-
ization-based method, its limitation is not being able to
distinguish between the gene and pseudogene targets.
Therefore, RDT is most appropriate for the CMD panel
because of the lower cost, ease of use, the length of the
target interval that is appropriate (65 Kbp), the ability to
distinguish between genes and pseudogenes, and the
ability to process eight samples per day.
From an assay validation perspective, the analytical
sensitivities of RDT and SS are similar, but lower than
Sanger sequencing (95%). The lower analytical sensi-
tivity may be explained by the lower coverage of specific
exons. However, the analytical specificities of RDT and
Sanger were higher than SS. Furthermore, RDT and
Sanger displayed a significantly higher reproducibility
than SS, as shown by the comparison of two samples
whose variants were tallied. For example, RDT data
showed a 99% variant call identity between the two
samples, whereas the SS was 85%. The analytical
specificity of all three methods taken together ap-
proached 100%. As part of a diagnostic plan, exons with
low coverage get reflexed to Sanger sequencing to en-
sure that no variants are missed. Therefore, RDT with
Sanger sequencing will continue to have the analytical
sensitivity of99% by virtue of using Sanger sequencing
for low-coverage exons.
Conclusions
Current single-gene approaches to identify mutations in
patient samples do not offer the throughput and ease of
use to screen the multiple genes often associated with
many medical genetic disorders, such as CMDs. Tar-
geted sequencing paired with NGS offers the first oppor-
tunity to effectively screen the complete coding regions
for a panel of genes in a single experiment. The two
targeted sequencing approaches evaluated in this study
(RDT and SS) demonstrated the ability to quickly and
accurately allow clinicians to simultaneously test a panel
of 12 genes associated with CMDs. Both RDT and SS
enrichment technologies proved suitable for use in a
clinical laboratory setting (Table 5). On the basis of our
findings, the RDT microdroplet-based PCR approach to
targeted sequencing stands out as the appropriate solu-
tion for a clinical laboratory. Irrespective of the enrich-
ment method used, some exons in highly repetitive and
GC-rich regions are difficult to target with both of these
approaches and will still require traditional Sanger se-
quencing. Our results support the notion that targetedmolecular diagnostics of heterogeneous genetic disor-
ders is now a reality. The adoption of a targeted sequenc-
ing approach in a clinical genetics laboratory will pave
the way for a significant improvement in the diagnosis of
heterogeneous genetic disorders and improve our under-
standing of disease genes.
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